KC
ARTL icon

Kepos Capital’s Artelo Biosciences ARTL Stock Holding History

Kepos Capital’s Portfolio ARTL Stock Details ARTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-741
Closed -$104K – 621
2021
Q4 		$104K Hold
741
– – 0.01% 504
2021
Q3 		$158K Hold
741
– – 0.01% 490
2021
Q2 		$238K Hold
741
– – 0.02% 388
2021
Q1 		$326K Sell
741
-185
-20% -$79.1K 0.02% 337
2020
Q4 		$183K Buy
+926
New +$159K 0.02% 292

Other funds holding ARTL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Kepos Capital's ARTL Position: Q1 2022 in Review

Kepos Capital sold out of Artelo Biosciences (ARTL) in Q1 2022, closing a stake of 741 shares — an estimated $104K sold.

Kepos Capital first reported a position in ARTL in Q4 2020 and held it in 5 quarters. The position peaked at $326K in Q1 2021. 18 funds tracked by Wall St. Rank hold ARTL as of Q1 2022.

  • Kepos Capital reported no remaining Artelo Biosciences position as of Q1 2022 after selling out during the quarter.
  • Kepos Capital sold 741 Artelo Biosciences shares in Q1 2022, an estimated $104K.
  • Kepos Capital first reported a position in Artelo Biosciences in Q4 2020 and held it in 5 quarters.
  • Kepos Capital's Artelo Biosciences position peaked at $326K in Q1 2021.
  • 18 funds tracked by Wall St. Rank held Artelo Biosciences as of Q1 2022.

Based on Kepos Capital's 13F filing for Q1 2022, filed 13 May 2022.